Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights - Episode 4

Expert Insights: How Tafasitamab + R2 May Impact Clinical Practice in R/R FL

January 11, 2025

Panelists discuss the potential impact of tafasitamab + R2 on clinical practice in relapsed/refractory follicular lymphoma, including initial thoughts on the combination of CD19 and CD20 in a phase 3 trial, identification of ideal patient candidates, and potential challenges or toxicity risks associated with this triplet regimen.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease

EP. 2: Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease

EP. 3: ASH 2024 Updates: inMIND study With Tafasitamab Combined With Lenalidomide and Rituximab in R/R FL

Now Viewing

EP. 4: Expert Insights: How Tafasitamab + R2 May Impact Clinical Practice in R/R FL

EP. 5: Exploring Tafasitamab in 2L Treatment: Challenges, Impact on Decision-Making, and Key Insights From inMIND Study

EP. 6: ASH 2024 Updates: EPCORE NHL-2 Trial With Fixed-Duration Epcoritamab + R2

EP. 7: Differentiating Treatment Options: Epcoritamab + R2 vs Tafasitamab-Lenalidomide-Rituximab in R/R FL

EP. 8: Choosing Bispecifics in 3L Treatment Setting R/R FL

EP. 9: ASH 2024 CAR T and Bispecifics Updates: Key Insights and Practical Considerations in 3L R/R FL Treatment

EP. 10: Navigating the Evolving Treatment Landscape in R/R FL: When to Consider BTK and EZH2 Inhibitors

EP. 11: Expert Perspectives: Sequencing Tafasitamab + R2 With Currently Available Options in 3L Setting

EP. 12: Reflecting on 2024: Key Achievements and Looking Ahead to 2025 in R/R FL Treatment

Video content above is prompted by the following:

This is the first time a CD19 has been combined with a CD20 in a phase 3 trial with positive results. What are your initial thoughts?
Which r/r FL patients would be the ideal candidate for this new tafasitamab + R2?
Are there any potential challenges or concerns with utilizing a triplet regimen with tafasitamab? Is there a risk for potential additional toxicities?